Published in J Womens Health on October 01, 1997
Structural and energetic basis of allostery. Annu Rev Biophys (2012) 1.51
Agonism/antagonism switching in allosteric ensembles. Proc Natl Acad Sci U S A (2012) 1.27
Visual spatial memory is enhanced in female rats (but inhibited in males) by dietary soy phytoestrogens. BMC Neurosci (2001) 1.07
Postmenopausal estrogen therapy and depressive symptoms in older women. J Gen Intern Med (2000) 0.96
Structural dynamics, intrinsic disorder, and allostery in nuclear receptors as transcription factors. J Biol Chem (2011) 0.96
The 2010 Philip S. Portoghese Medicinal Chemistry Lectureship: addressing the "core issue" in the design of estrogen receptor ligands. J Med Chem (2011) 0.95
Interplay between allostery and intrinsic disorder in an ensemble. Biochem Soc Trans (2012) 0.89
Pomegranate fruit as a rich source of biologically active compounds. Biomed Res Int (2014) 0.89
Manipulation of prenatal hormones and dietary phytoestrogens during adulthood alter the sexually dimorphic expression of visual spatial memory. BMC Neurosci (2001) 0.83
Dual Allosteric Inhibitors Jointly Modulate Protein Structure and Dynamics in the Hepatitis C Virus Polymerase. Biochemistry (2015) 0.76
Identification and characterization of potential impurities in raloxifene hydrochloride. Sci Pharm (2012) 0.75
Disordered allostery: lessons from glucocorticoid receptor. Biophys Rev (2015) 0.75
Inhibition of glycinamide ribonucleotide formyltransferase results in selective inhibition of macrophage cytokine secretion in vitro and in vivo efficacy in rat adjuvant arthritis. Clin Exp Rheumatol (2005) 1.38
Duration and death in systemic lupus erythematosus. An analysis of 249 cases. JAMA (1974) 1.28
Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med (2000) 1.17
Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J (1996) 1.14
Emerging therapies for the prevention or treatment of postmenopausal osteoporosis. J Med Chem (1999) 1.13
Environmental estrogens: effects on cholesterol lowering and bone in the ovariectomized rat. J Steroid Biochem Mol Biol (1996) 1.10
Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci U S A (1997) 1.10
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J Med Chem (1997) 1.09
Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator. J Med Chem (1997) 1.07
Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann N Y Acad Sci (1995) 1.07
Familial systemic lupus erythematosus. Arch Intern Med (1978) 1.06
Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980. Am J Med (1982) 1.05
Biochemical effects of estrogen on articular cartilage in ovariectomized sheep. Osteoarthritis Cartilage (1997) 1.02
Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res (2001) 0.97
Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity. J Steroid Biochem Mol Biol (1997) 0.92
Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J Pharmacol Exp Ther (1995) 0.90
The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology (1994) 0.90
Intermittent administration of bovine PTH-(1-34) increases serum 1,25-dihydroxyvitamin D concentrations and spinal bone density in senile (23 month) rats. J Bone Miner Res (1992) 0.90
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators. J Med Chem (1998) 0.89
Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats. J Pharmacol Exp Ther (1996) 0.89
Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats. Brain Res (1999) 0.89
Differential effects of estrogen and raloxifene on messenger RNA and matrix metalloproteinase 2 activity in the rat uterus. Biol Reprod (2004) 0.89
Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology (1994) 0.88
No direct neuronotoxicity by HIV-1 virions or culture fluids from HIV-1-infected T cells or monocytes. AIDS Res Hum Retroviruses (1992) 0.88
Selective estrogen receptor modulators: tissue selectivity and differential uterine effects. Climacteric (1999) 0.88
Morphine-induced alterations in plasma and tissue cholesterol levels. Life Sci (1987) 0.87
Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology (1996) 0.86
Effects of human growth hormone on body composition in elderly men. Horm Res (1991) 0.86
Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporos Int (1999) 0.86
LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther (1998) 0.85
Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. Endocrinology (1996) 0.84
The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing. Reprod Toxicol (1998) 0.84
Photoaffinity labeling of the canine renal receptor for parathyroid hormone. J Biol Chem (1982) 0.84
The effect of raloxifene on coronary arteries in aged ovariectomized ewes. J Vet Pharmacol Ther (2000) 0.83
Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol (1997) 0.83
Mechanism of action of estrogens and selective estrogen receptor modulators. Vitam Horm (2000) 0.83
Effect of weight manipulation on bone loss due to ovariectomy and the protective effects of estrogen in the rat. Calcif Tissue Int (1993) 0.83
The nongenotropic synthetic ligand 4-estren-3alpha17beta-diol is a high-affinity genotropic androgen receptor agonist. Mol Pharmacol (2004) 0.83
Endemic infection of a cat colony with a feline calicivirus closely related to an isolate used in live attenuated vaccines. Vaccine (2001) 0.83
Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations. Clin Endocrinol (Oxf) (1993) 0.83
Molecular structure, conformation and interactions of antitumor antibiotic cyanonaphthridinomycin, a covalent binder of DNA. J Biomol Struct Dyn (1988) 0.82
Synthetic position 5 analogs of adrenocorticotropin fragments and their in vitro lipolytic activity. Biochemistry (1975) 0.82
Anti-inflammatory activity of pergolide, a dopamine receptor agonist. J Pharmacol Exp Ther (1991) 0.81
Differential responses of estrogen target tissues in rats including bone to clomiphene, enclomiphene, and zuclomiphene. Endocrinology (1998) 0.81
Lipolytic activity of Met-Arg-His-Phe-Arg-Trp-Gly, a synthetic analog of the ACTH (4-10) core sequence. J Med Chem (1973) 0.80
Raloxifene and estrogen: comparative bone-remodeling kinetics. J Clin Endocrinol Metab (1997) 0.80
Dissociation of immunosuppression by chlorpromazine and trifluoperazine from pharmacologic activities as dopamine antagonists. Int J Immunopharmacol (1991) 0.80
Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J Bone Miner Res (1994) 0.79
Stress, endogenous opioids and salt intake. Appetite (1984) 0.79
Serotonin-induced paw edema in the rat: pharmacological profile. Gen Pharmacol (1995) 0.78
Pharmacologic manipulation of graft versus host induced splenomegaly. Agents Actions (1992) 0.78
The selective oestrogen receptor modulator, LY362321, is not neuroprotective in a rat model of transient focal ischaemia. J Neuroendocrinol (2008) 0.78
Evidence for separate peptide sequences related to the lipolytic and magnesium-accumulating activities of ACTH. Analogy with adrenergic receptors. J Med Chem (1977) 0.78
Central and peripheral temperature changes in sheep following ovariectomy. Maturitas (2003) 0.78
Effects of wortmannin analogs on bone in vitro and in vivo. J Pharmacol Exp Ther (1996) 0.77
Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator. J Pharmacol Exp Ther (1997) 0.77
Conditioned immunosuppression of a murine delayed type hypersensitivity response: dissociation from corticosterone elevation. Brain Behav Immun (1991) 0.77
Opioid and non-opioid components of insulin-induced feeding. Pharmacol Biochem Behav (1986) 0.76
Dose-response effects of estradiol implants on bone mineral density in ovariectomized ewes. Bone (1995) 0.76
Comment on lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab (1998) 0.75
Steroidogenic activity of fragments of adrenocorticotropin with arginine in residue positions 3 and 5. Proc Natl Acad Sci U S A (1977) 0.75
Effects of 2% sodium chloride imbibition on various opiate related hyperphagic conditions. Pharmacol Biochem Behav (1985) 0.75
Clomiphene prevents cancellous bone loss from tibia of ovariectomized rats. Endocrinology (1997) 0.75
Presence of dynorphin-like immunoreactivity but not opiate binding in Walker-256 tumors. Life Sci (1985) 0.75
Dietitians of the future. Dietitians, the Department of Health and Social Security and the National Health Service. J Hum Nutr (1977) 0.75
Effects of prolonged ethinyl estradiol treatment on calcium channel binding and in vivo calcium-mediated hemodynamic responses in ovariectomized rats. J Pharmacol Exp Ther (1997) 0.75
Dual-energy X-ray absorptiometry in sheep: experiences with in vivo and ex vivo studies. Bone (1995) 0.75
Biosynthetic human growth hormone in the treatment of growth hormone deficiency. Acta Paediatr Scand Suppl (1990) 0.75
Distinct form of osteosclerosis in identical twins with mental retardation. AJR Am J Roentgenol (1982) 0.75
Assessment of dynorphin-A depletion in the anorexia of Walker-256 tumor bearing rats. Physiol Behav (1985) 0.75
Raloxifene: a new choice for treating and preventing osteoporosis. Cleve Clin J Med (2000) 0.75
Survival in corticosteroid-treated patients with systemic lupus erythematosus. JAMA (1978) 0.75
Structural, conformational, and theoretical binding studies of antitumor antibiotic porfiromycin (N-methylmitomycin C), a covalent binder of DNA, by X-ray, NMR, and molecular mechanics. J Med Chem (1990) 0.75
Photochemical synthesis of N-arylbenzophenanthridine selective estrogen receptor modulators (serms). J Med Chem (2001) 0.75
Differential inhibition by propranolol of feeding induced in rats by various stimuli. Pharmacol Biochem Behav (1984) 0.75
CNS tissue levels of dynorphin-A immunoreactivity and the anorexia associated with sodium chloride imbibition in the rat. Peptides (1985) 0.75
Functional mediastinal parathyroid cyst. Dynamics of parathyroid hormone secretion during cyst aspirations and surgery. Am J Med (1985) 0.75
Approaching final height in children treated for growth hormone deficiency. Horm Res (1995) 0.75
The structure of parathyroid hormone: its effects on biological action. Miner Electrolyte Metab (1983) 0.75
Pharmacologic manipulation of a four day murine delayed type hypersensitivity model. Agents Actions (1993) 0.75
Nocturnal depletion of hypothalamic dynorphin in anorexic Walker-256 tumor-bearing rats. Pharmacol Biochem Behav (1988) 0.75
An assay for N 5 -methyltetrahydrofolate-homocysteine transmethylase activity using instant thin-layer chromatography. Anal Biochem (1972) 0.75